Physical Properties
Recommended Separation Techniques
The industry-standard mAb platform process, ranked by sequence and importance.
The cornerstone of mAb purification. Protein A ligands bind the Fc region of IgG with high specificity (Kd ~10 nM). Harvest is loaded at pH 7.0–7.4, washed, and eluted at pH 3.0–3.5. Achieves >95% purity in a single step with >99% HCP removal. Dynamic binding capacity: 30–50 g/L resin. Recovery: 95–99%. This single step transforms crude cell culture harvest into near-pure IgG.
IgG is positively charged at pH 5.0 (below pI), binding to CEX resins while most HCP impurities flow through. Gradient or step elution with NaCl resolves charge variants (acidic/basic species) and removes aggregates. Operated in bind-and-elute mode. Removes residual HCP, leached Protein A, and aggregates. Recovery: 90–95%.
Operated in flow-through mode at pH 7.5–8.5 where IgG carries net positive charge and passes through. DNA (highly negative), endotoxin, and acidic HCP bind to the AEX resin and are removed. Also provides viral clearance (>4 log reduction for retroviruses). Simple, high-throughput polishing step.
Final formulation step using 30–50 kDa MWCO TFF cassettes. Concentrates IgG from ~5 g/L to 50–200 g/L for subcutaneous injection, and performs buffer exchange (diafiltration) into the final formulation buffer. Also removes small-molecule impurities, salts, and process buffers. Recovery: >97%.
Common Impurity Separations
| Separate From | Key Difference | Best Technique | Selectivity Basis |
|---|---|---|---|
| Host Cell Proteins (HCP) | Fc binding (IgG-specific vs non-binding) | Protein A Affinity | Biospecific Fc recognition |
| Host Cell DNA | Charge (IgG + vs DNA −−) | AEX (flow-through mode) | Charge-based binding |
| IgG Aggregates | Size (150 kDa monomer vs >300 kDa) | CEX / HIC / SEC | Size & hydrophobicity |
| Leached Protein A | Charge & size (42 kDa, acidic pI) | CEX (bind-elute) | Charge difference at pH 5 |
| Viruses | Size (20–300 nm) & charge | Viral Filtration (20 nm) + AEX | Size exclusion & charge |
Platform Process Architecture
The mAb platform process is one of the most standardized and well-characterized purification trains in biotechnology.
Standard Three-Column Platform
The industry consensus platform for IgG purification consists of three chromatographic steps bracketed by clarification and formulation:
| Step | Operation | Purpose | Purity After |
|---|---|---|---|
| 1 | Depth Filtration + 0.2 μm MF | Cell & debris removal | ~60–70% |
| 2 | Protein A Chromatography | Capture & primary purification | >95% |
| 3 | Low pH Viral Inactivation | Retrovirus inactivation (pH 3.5, 60 min) | >95% |
| 4 | CEX Chromatography | Aggregate & HCP removal | >99% |
| 5 | AEX Chromatography (flow-through) | DNA, endotoxin, virus clearance | >99.5% |
| 6 | Viral Filtration (20 nm) | Parvovirus clearance | >99.5% |
| 7 | UF/DF (30 kDa MWCO) | Concentration & buffer exchange | >99.5% |
Frequently Asked Questions
Why is Protein A chromatography so dominant in mAb purification?
Protein A binds the Fc region of IgG with extraordinary specificity (Kd ~10 nM), achieving >95% purity in a single step from crude cell culture harvest. No other chromatographic method offers this combination of selectivity, capacity (30–50 g/L), and robustness. Despite the high resin cost ($8,000–15,000/L), it reduces overall downstream costs by eliminating multiple intermediate steps. Design your mAb process with untangle.bio.
How do you remove IgG aggregates?
Aggregates (dimers, trimers, higher-order species) are a critical quality attribute for biotherapeutics. Cation exchange chromatography (CEX) in bind-and-elute mode resolves monomers from aggregates based on charge and avidity differences. Hydrophobic interaction chromatography (HIC) exploits the greater hydrophobic surface exposure of aggregates. Size exclusion chromatography (SEC) separates by size but has low capacity and is mainly analytical.
What viral clearance steps are required for mAb manufacturing?
Regulatory guidelines (ICH Q5A) require demonstration of orthogonal viral clearance. The standard approach includes: (1) low pH hold at pH 3.5 for 60 minutes (inactivates enveloped viruses like retroviruses), (2) AEX chromatography in flow-through mode (>4 log retrovirus clearance), and (3) nanofiltration through 20 nm filters (removes parvoviruses and other small non-enveloped viruses). Combined clearance typically exceeds 12–18 log reduction.
Can mAbs be purified without Protein A?
Yes, Protein A-free platforms use multimodal or mixed-mode chromatography (e.g., Capto MMC for capture, followed by CEX and AEX). These reduce resin costs but typically require more process development and may have lower step yields. Alternatives include cation exchange capture at low pH, precipitation with PEG or caprylic acid, and aqueous two-phase extraction. Non-Protein A platforms are gaining interest for biosimilars where cost is paramount.
Related Molecules
Design Your mAb Purification Process
Build and simulate complete downstream processing routes with real mass balance and cost estimation.
Open untangle.bio